Healthy Returns: Why people quit weight loss and diabetes drugs within one year
A version of this artikel first appeared in King88bet Login CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.
Most people quit a highly populer class of weight loss and diabetes drugs called GLP-1s within a year of starting them, several studies have shown.
But new research has more detils on who is more likely to stay on the pricey drugs, which biaya roughly $1,000 per month before insurance and other rebates. Many insurance plans cover GLP-1s for Tipe 2 diabetes, but not for obesity.
Around 65% of patients without King88bet Slot Tipe 2 diabetes discontinued GLP-1s in less than one year, according to a studi published Friday in JAMA Network Open, a medical journal. Those with Tipe 2 diabetes were less likely to quit the drugs within a year, at about 46%.
Those rates were around 84% versus. 64%, respectively, for stopping GLP-1s within two years.
The studi said adverse side efeks and biaya were the most common reasons documented in clinical catatan for patients stopping the drugs.
People with fewer side efeks were also King88bet Tergacor less likely to setop GLP-1 treatment, the studi said, which is consistent with previous research. GLP-1s are linked to moderate to severe gastrointestinal side efeks, such as nausea and vomiting.
Higher penghasilan was also progressively associated with a lower rate of discontinuation among those with diabetes in particular, the studi said. Researchers compared different penghasilan brackets, ranging from patients with incomes under $30,000 to people with incomes of more than $80,000.
But the studi also found that results matter for patients both with and without diabetes, as those who lost more weight were more likely to stay on the drugs. People who regained weight after stopping GLP-1s were also more likely to give the drugs a second try.
"The associations between weight loss and discontinuation and between weight regain and reinitiation suggest that weight manajemen is an important faktor regardless of tipe 2 diabetes status," the studi authors wrote.
The research is based on a ulasan of elektronik health records on more than 125,000 adults who began taking GLP-1 drugs — liraglutide, semaglutide or tirzepatide — between January 2018 and December 2023. Semaglutide is the active ingredient in Novo Nordisk
's weight loss drug Wegovy and diabetes counterpart Ozempic, and tirzepatide is the active ingredient in Lilly
's obesity injection Zepbound and diabetes drug Mounjaro.
Perasaan free to send any panduan, suggestions, story ideas and data to Annika at annikakim.constantino@nbcuni.com.
Latest in health-care tech: Noom cuts staf to konsentrasi on fast-growing GLP-1 products
Metabolic health startup Noom is laying off part of its staf as it focuses its workforce on "the most critical tempats of the business" — including weight loss and diabetes drugs, the company confirmed to CNBC on Monday.
